Market Overview:
The global tumor markers immunoassay market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, technological advancements in tumor marker immunoassays, and rising demand for early diagnosis and treatment of cancer. Based on type, the global tumor markers immunoassay market is segmented into proGRP, PSA (complexed, free, total), SCC (squamous cell carcinoma antigen), serum HER-2/neu, thyroglobulin, CA 72-4 and others. Based on application, the global tumor markers immunoassay market is segmented into liver cancer breast cancer and others. North America dominates the global tumor markers immunoassay market followed by Europe due to high prevalence of various types of cancers in these regions.
Product Definition:
A tumor marker immunoassay is a blood or tissue test that checks for certain proteins, enzymes, or other substances that are produced by cancer cells. The presence of these markers may suggest that a person has cancer.
ProGRP:
ProGMP is a protein that plays an important role in the regulation of cell growth and differentiation. It is also known as gastric tumor-associated protein (tPA), which indicates its function in stomach tumors. ProGMP has been studied extensively due to its potential use as a noninvasive biomarker for diagnosis and monitoring of gastrointestinal malignancies, including adenocarcinoma, carcinoid tumor, SCCLomas intestinal type II, and others.
PSA (complexed, free, total)):
PSA (Prostate-specific Antigen) is an antigen found in prostate cancer cells. It can be used as a tumor marker for immunoassay procedures. PSA levels are usually higher in prostate cancer patients than the general population due to the presence of high testosterone and other growth factors that stimulate the growth of these cells.
Application Insights:
The breast cancer segment dominated the global tumor markers immunoassay market in 2017. This can be attributed to the increasing prevalence of breast cancer and availability of several diagnostic options such as blood tests that are sensitive to tumor-specific antigens. For instance, a test known as Oncotype Dx is used for the detection of ductal carcinoma in situ (DCIS) which is highly specific for this type of cancer.
Moreover, other factors responsible for market growth include advancements made in immunochemistry techniques along with rising R&D initiatives undertaken by key players such as Roche and Merck Millipore to develop novel products with enhanced accuracy and sensitivity.
Regional Analysis:
North America dominated the global tumor markers immunoassay market in 2017. This can be attributed to presence of well-established healthcare facilities, availability of advanced diagnostic techniques and high patient awareness levels coupled with relatively higher healthcare expenditure in this region as compared to other regions. In addition, favorable reimbursement policies for immunoassays are also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to increasing prevalence of cancer among Asian population along with growing disposable income and improved lifestyle associated factors such as smoking & alcohol consumption rates especially among men which increases their susceptibility towards developing various types of cancers at a faster rate than women resulting into an increased demand for accurate diagnostic procedures thus driving its growth over past few years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for tumor markers immunoassay market. According to World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase by about 70% over next two decades, making it one of the leading causes of death globally. This will create demand for better and more accurate diagnostic tests such as tumor markers immunoassay, which can help in early diagnosis and treatment of the disease.
- Rising awareness about benefits of early diagnosis: There is growing awareness among people about benefits associated with early diagnosis and treatment of cancers such as improved survival rates and quality life expectancy etcetera .This is driving demand for better diagnostic tests such as tumor markers immunoassay that can help in early detection/diagnosisof cancers .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Markers Immunoassay Market Research Report
By Type
ProGRP, PSA (complexed, free, total)), SCC (squamous cell carcinoma antigen), Serum HER-2/neu, Thyroglobulin, CA 72-4, Others
By Application
Liver Cancer, Breast Cancer, Others
By Companies
Clarity Diagnostics, LLC, CTK Biotech, Inc, DIALAB GmbH, Ortho Clinical Diagnostics, Polymedco, Inc, DIAsource ImmunoAssays SA, DRG International, Inc, Fujirebio US, Inc, Bioscience (Tianjin) Diagnostic Technology Co., Ltd, Boson Biotech Co., Ltd, Qualigen, Inc, Randox Laboratories, Ltd, Roche Diagnostic Corporation, Siemens Healthineers, Syntron Bioresearch, Inc, Teco Diagnostics, Thermo Fisher Scientific, Inc, Tosoh Bioscience, Inc, Diametra, DiaSorin S.p.A
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
130
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Markers Immunoassay Market Report Segments:
The global Tumor Markers Immunoassay market is segmented on the basis of:
Types
ProGRP, PSA (complexed, free, total)), SCC (squamous cell carcinoma antigen), Serum HER-2/neu, Thyroglobulin, CA 72-4, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Liver Cancer, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Clarity Diagnostics, LLC
- CTK Biotech, Inc
- DIALAB GmbH
- Ortho Clinical Diagnostics
- Polymedco, Inc
- DIAsource ImmunoAssays SA
- DRG International, Inc
- Fujirebio US, Inc
- Bioscience (Tianjin) Diagnostic Technology Co., Ltd
- Boson Biotech Co., Ltd
- Qualigen, Inc
- Randox Laboratories, Ltd
- Roche Diagnostic Corporation
- Siemens Healthineers
- Syntron Bioresearch, Inc
- Teco Diagnostics
- Thermo Fisher Scientific, Inc
- Tosoh Bioscience, Inc
- Diametra
- DiaSorin S.p.A
Highlights of The Tumor Markers Immunoassay Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ProGRP
- PSA (complexed, free, total))
- SCC (squamous cell carcinoma antigen)
- Serum HER-2/neu
- Thyroglobulin
- CA 72-4
- Others
- By Application:
- Liver Cancer
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Markers Immunoassay Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A tumor markers immunoassay is a laboratory test that uses antibodies to detect the presence of specific tumor markers in a sample. These tests can be used to help diagnose cancer and monitor the progress of treatment.
Some of the major companies in the tumor markers immunoassay market are Clarity Diagnostics, LLC, CTK Biotech, Inc, DIALAB GmbH, Ortho Clinical Diagnostics, Polymedco, Inc, DIAsource ImmunoAssays SA, DRG International, Inc, Fujirebio US, Inc, Bioscience (Tianjin) Diagnostic Technology Co., Ltd, Boson Biotech Co., Ltd, Qualigen, Inc, Randox Laboratories, Ltd, Roche Diagnostic Corporation, Siemens Healthineers, Syntron Bioresearch, Inc, Teco Diagnostics, Thermo Fisher Scientific, Inc, Tosoh Bioscience, Inc, Diametra, DiaSorin S.p.A.
The tumor markers immunoassay market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tumor Markers Immunoassay Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tumor Markers Immunoassay Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tumor Markers Immunoassay Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tumor Markers Immunoassay Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tumor Markers Immunoassay Market Size & Forecast, 2020-2028
4.5.1 Tumor Markers Immunoassay Market Size and Y-o-Y Growth
4.5.2 Tumor Markers Immunoassay Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ProGRP
5.2.2 PSA (complexed
5.2.3 free
5.2.4 total))
5.2.5 SCC (squamous cell carcinoma antigen)
5.2.6 Serum HER-2/neu
5.2.7 Thyroglobulin
5.2.8 CA 72-4
5.2.9 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Liver Cancer
6.2.2 Breast Cancer
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tumor Markers Immunoassay Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tumor Markers Immunoassay Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ProGRP
9.6.2 PSA (complexed
9.6.3 free
9.6.4 total))
9.6.5 SCC (squamous cell carcinoma antigen)
9.6.6 Serum HER-2/neu
9.6.7 Thyroglobulin
9.6.8 CA 72-4
9.6.9 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Liver Cancer
9.10.2 Breast Cancer
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ProGRP
10.6.2 PSA (complexed
10.6.3 free
10.6.4 total))
10.6.5 SCC (squamous cell carcinoma antigen)
10.6.6 Serum HER-2/neu
10.6.7 Thyroglobulin
10.6.8 CA 72-4
10.6.9 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Liver Cancer
10.10.2 Breast Cancer
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ProGRP
11.6.2 PSA (complexed
11.6.3 free
11.6.4 total))
11.6.5 SCC (squamous cell carcinoma antigen)
11.6.6 Serum HER-2/neu
11.6.7 Thyroglobulin
11.6.8 CA 72-4
11.6.9 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Liver Cancer
11.10.2 Breast Cancer
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ProGRP
12.6.2 PSA (complexed
12.6.3 free
12.6.4 total))
12.6.5 SCC (squamous cell carcinoma antigen)
12.6.6 Serum HER-2/neu
12.6.7 Thyroglobulin
12.6.8 CA 72-4
12.6.9 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Liver Cancer
12.10.2 Breast Cancer
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ProGRP
13.6.2 PSA (complexed
13.6.3 free
13.6.4 total))
13.6.5 SCC (squamous cell carcinoma antigen)
13.6.6 Serum HER-2/neu
13.6.7 Thyroglobulin
13.6.8 CA 72-4
13.6.9 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Liver Cancer
13.10.2 Breast Cancer
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tumor Markers Immunoassay Market: Competitive Dashboard
14.2 Global Tumor Markers Immunoassay Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Clarity Diagnostics, LLC
14.3.2 CTK Biotech, Inc
14.3.3 DIALAB GmbH
14.3.4 Ortho Clinical Diagnostics
14.3.5 Polymedco, Inc
14.3.6 DIAsource ImmunoAssays SA
14.3.7 DRG International, Inc
14.3.8 Fujirebio US, Inc
14.3.9 Bioscience (Tianjin) Diagnostic Technology Co., Ltd
14.3.10 Boson Biotech Co., Ltd
14.3.11 Qualigen, Inc
14.3.12 Randox Laboratories, Ltd
14.3.13 Roche Diagnostic Corporation
14.3.14 Siemens Healthineers
14.3.15 Syntron Bioresearch, Inc
14.3.16 Teco Diagnostics
14.3.17 Thermo Fisher Scientific, Inc
14.3.18 Tosoh Bioscience, Inc
14.3.19 Diametra
14.3.20 DiaSorin S.p.A
